TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00944918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fulvestrant
Description: Intramuscular injection on days 1, 15, and 29 and then once monthly until disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fulvestrant
Description: Intramuscular injection on days 1, 15, and 29 and then once monthly until disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anastrozole
Description: Tablet, oral, once daily until disease progression.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: exemestane
Description: Tablet, oral, once daily until disease progression.
Study: NCT05181098

Intervention type: PROCEDURE
Intervention: Robotic-guided spine surgery
Description: The Mazor X Stealth Edition robotic platform will be used to guide posterior instrumentation during spine fusion surgery.
Study: NCT03988361

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Activated Cell Sorting
Description: At the moment of ICSI, sibling mature oocytes will be inseminated with spermatozoa from Study group or from Control group. Following ICSI, all the inseminated oocytes will be individually cultured in the same conditions in the same culture dish. The choice of embryo(s) for transfer will be based on embryo quality. The supernumerary good-quality embryos from both arms will be frozen for further use.
Study: NCT00764101

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attentional Bias Modification
Description: computerized training to reduce attentional bias in posttraumatic stress disorder

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attentional Bias Modification
Description: computerized training to reduce attentional bias in posttraumatic stress disorder
Study: NCT03361462

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Joyful Adventure Day
Description: Participants will participate in two joyful adventure days with adventure games and a short talk on SME (Sharing, Mind, Enjoyment) focusing on positive thinking and understanding of adolescent mental health problem (in particular the anxiety disorders) and mental well-being; provide physical activity diary, such as Zero-time Exercise after 1st session of adventure day, and invite family members / peers to join the competition at the 2nd session.
Study: NCT03885414

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-session Virtual Reality exposure therapy
Description: A series of exposure exercises (speech exercises) in front of a virtual audience, focusing on promoting inhibitory learning, with audio-feedback.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-administered transition program
Description: Four-module internet program with weekly therapist guidance, focusing on transitioning to in-vivo exposure in everyday settings.
Study: NCT01696552

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TKR with Conventional Technique
Description: TKR (Vanguard Total Knee System, Biomet) with Conventional Technique
Study: NCT05702697

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: focus extracorporeal shock wave therapy
Description: F-EWST with 0.15 mJ/mm2 intensity and 6 Hz frequency for 3 weeks. The shocking head was placed at the muscle positions of the long head of the bicep femoris, semitendinosus, and semimembranosus for 1,000, 500, and 500 shocks, respectively, accounting for 2,000 shocks in total/ session/week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home stretching program
Description: The leaflet on hamstring stretching exercises (in a sitting posture)

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Home stretching program
Description: The leaflet on hamstring stretching exercises (in a sitting posture)
Study: NCT04310930

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amikacin
Description: Adults: Intravenous amikacin 5mg/kg once daily or 7.5mg/kg twice daily or 20-25 mg/kg thrice weekly. Children:Intravenous amikacin 15-30 mg/kg once daily, maximum dose 1500mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amikacin
Description: Adults: Intravenous amikacin 5mg/kg once daily or 7.5mg/kg twice daily or 20-25 mg/kg thrice weekly. Children:Intravenous amikacin 15-30 mg/kg once daily, maximum dose 1500mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tigecycline
Description: Adults: Intravenous Tigecycline 25 mg increasing by 5 mg every two doses until either maximum dose reached (50mg) or until patient is unable to tolerate twice daily. Children (≥8 years of age) intravenous tigecycline: Day 1- 0.6mg/kg twice daily to a maximum of 25mg. Day 2- 0.6mg/kg (maximum 25mg) in the morning, 1.2 mg/kg (maximum 50mg) at night. Day 3- 1.2mg/kg (maximum 50 mg) twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tigecycline
Description: Adults: Intravenous Tigecycline 25 mg increasing by 5 mg every two doses until either maximum dose reached (50mg) or until patient is unable to tolerate twice daily. Children (≥8 years of age) intravenous tigecycline: Day 1- 0.6mg/kg twice daily to a maximum of 25mg. Day 2- 0.6mg/kg (maximum 25mg) in the morning, 1.2 mg/kg (maximum 50mg) at night. Day 3- 1.2mg/kg (maximum 50 mg) twice daily
Study: NCT02861508

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Point-of-care ultrasound

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Study: NCT01095835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon (PEG-IFN) alfa-2a, 180 mcg
Description: PEG-IFN alfa-2a 180 micrograms (mcg) was administered subcutaneously, once weekly from Week 0 to 48.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon (PEG-IFN) alfa-2a, 180 mcg
Description: PEG-IFN alfa-2a 180 micrograms (mcg) was administered subcutaneously, once weekly from Week 0 to 48.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon (PEG-IFN) alfa-2a, 180 mcg
Description: PEG-IFN alfa-2a 180 micrograms (mcg) was administered subcutaneously, once weekly from Week 0 to 48.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon (PEG-IFN) alfa-2a, 135 mcg
Description: PEG-IFN alfa-2a 135 mcg was administered subcutaneously, once weekly from Week 49 to 96.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon (PEG-IFN) alfa-2a, 135 mcg
Description: PEG-IFN alfa-2a 135 mcg was administered subcutaneously, once weekly from Week 49 to 96.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine (LAM)
Description: Lamivudine 100 milligrams (mg) was administered orally, daily from Week 0 to 48.
Study: NCT01786057

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal shock wave therapy 1
Description: Extracorporeal shock wave therapy , (3000 shock waves/session of 0.2 mJ/mm2) for heel region and (400 shock waves/session of 0.2 mJ/mm2 per each trigger point) for gastrosoleus trigger points , 3 sessions at weekly intervals

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Extracorporeal shock wave therapy 2
Description: Extracorporeal shock wave therapy , (3000 shock waves/session of 0.2 mJ/mm2) for heel region , 3 sessions at weekly intervals
Study: NCT00350883

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy
Description: Goal-oriented talk therapy

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as Usual
Description: Keep getting usual care
Study: NCT04437758

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Collagen and Vitamin C powder mix nutritional intervention
Description: 20 g collagen + 50 mg vitamin C daily, 60 min prior to exercise

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin placebo powder
Description: 20 g maltodextrin placebo daily, 60 min prior to exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maximum power training exercise
Description: Explosive/power-based exercise training program 3 times/week at home consisting of drop jumps, box jumps, weighted jump squats loaded in a progressive manner weekly for 3 weeks. At baseline and at the end of each of the 3 weeks, measures of explosive performance are assessed in the lab (maximal isometric squat, counter-movement jump and squat jump)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Maximum power training exercise
Description: Explosive/power-based exercise training program 3 times/week at home consisting of drop jumps, box jumps, weighted jump squats loaded in a progressive manner weekly for 3 weeks. At baseline and at the end of each of the 3 weeks, measures of explosive performance are assessed in the lab (maximal isometric squat, counter-movement jump and squat jump)
Study: NCT03959007

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aesthetic therapy sessions
Description: Only for experimental arm at 3 times during hospitalization

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire
Description: Both arm at 3 times during hospitalization

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Both arm at 3 times during hospitalization
Study: NCT02477176

Intervention type: OTHER
Intervention: Discectomy
Description: Lumbar discectomy

Intervention type: OTHER
Intervention: Discectomy
Description: Lumbar discectomy
Study: NCT03856372

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated
Description: daily fractions, five fractions per week.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional
Description: daily fractions, five fractions per week.
Study: NCT03041389

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CCBT-I Group
Description: Every patient will have a unique password to access to CCBT-I. The program consists of 5 cores: sleep log, day's lesson, activities, relaxation and progress. Each day, the patients fill in sleep logs before getting the day's lesson. Filling sleep log will be reminded daily by the program coach from Sleep Center.
Study: NCT02315300

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: medilog® DARWIN FD12

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring
Study: NCT01056900

Intervention type: PROCEDURE
Intervention: Autologous Chondrocyte Implantation
Description: * Test drug: Chondron (more than 12 million chondrocytes in 0.4ml, i.e. 1 vial)~* Directions and dosage:~Suspend the cells in the vial sufficiently, and implant them in the defective part, making sure that sufficient amounts are injected.
Study: NCT03057522

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Change in running cadence
Description: The intervention will involve a home exercise program designed to increase the running cadence in recreational runners.
Study: NCT01293045

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: hydrolyzed collagen
Description: 10g/day at breakfast during 90 days

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: wheat protein
Description: 10g/day at breakfast during 90 days
Study: NCT02294903

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coiled Bipolar Radiofrequency Ablation
Description: Radiofrequency ablation by use of bipolar electrodes
Study: NCT03041389

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Reading material only including recommendations about sleep hygiene, stimulus control and sleep restriction. Access to the CCBT-I program through the internet (Cleveland Clinic Wellness Go! To Sleep six-week online program), if proven effective, after the study is completed.
Study: NCT03745742

Intervention type: OTHER
Group type: OTHER
Intervention: HRV measurement
Description: Patients in group A (control) will benefit from a standard re-training protocol based on initial functional abilities. The training is done at a target heart rate corresponding to the heart rate reached at the first ventilatory threshold (about 55% of VO2max).~* Patients in group B (study strategy) will benefit from a re-training protocol based on HRV and initial functional abilities. Any increase in HRV compared to the previous day will result in an increase in workload of 10Watt. Any increase or decrease in HRV for 3 days in a row will cause the stagnation of the workload for 2 days.~HRV is measured every day in each group via a heart rate belt and a smartphone App.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HRV measurement
Description: Patients in group A (control) will benefit from a standard re-training protocol based on initial functional abilities. The training is done at a target heart rate corresponding to the heart rate reached at the first ventilatory threshold (about 55% of VO2max).~* Patients in group B (study strategy) will benefit from a re-training protocol based on HRV and initial functional abilities. Any increase in HRV compared to the previous day will result in an increase in workload of 10Watt. Any increase or decrease in HRV for 3 days in a row will cause the stagnation of the workload for 2 days.~HRV is measured every day in each group via a heart rate belt and a smartphone App.
Study: NCT01437618

Intervention type: DRUG
Intervention: FOLFOXIRI plus bevacizumab
Description: * BEVACIZUMAB 5 mg/Kg i.v. over 30', day 1 followed by~* IRINOTECAN 165 mg/sqm i.v. over 1-h, day 1 followed by~* OXALIPLATIN 85 mg/sqm i.v. over 2-h, day 1 concomitantly with~* l-LV 200 mg/sqm i.v. over 2-h, day 1 followed by~* 5-FLUOROURACIL 3200 mg/sqm i.v. 48-h continuous infusion, starting on day 1 Cycles repeated every 2 weeks
Study: NCT03619447

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ESP block group
Description: USG guided Erector spinae block (ESP) will perform bilaterally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: serratus block group
Description: USG guided serratus plane block will perform bilaterally
Study: NCT03704623

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Paracetamol 1g IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Parecoxib
Description: Parecoxib 40 mg IV
Study: NCT01608126

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cervical block
Description: In brief, the superficial block was performed using a 22G needle (07 x 40 mm). The mixture injected was 15 ml of 0.5% bupivacaine + 10 ml of 1% lidocaine. Deep cervical plexus block was performed using a Stimuplex DR stimulating needle and the dose of anaesthetic used was 10 ml 0.5% bupivacaine + 5 ml 1% lidocaine applied in the vicinity of the C3 nerve root.~The MCPB performed using ultrasound-guidance aiming specifically for the interfascia space. Eighteen ml of 0.375% bupivacaine was injected into the interfascia space at the level of C3 vertebral body using a 22G needle (07 x 40 mm).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cervical block
Description: In brief, the superficial block was performed using a 22G needle (07 x 40 mm). The mixture injected was 15 ml of 0.5% bupivacaine + 10 ml of 1% lidocaine. Deep cervical plexus block was performed using a Stimuplex DR stimulating needle and the dose of anaesthetic used was 10 ml 0.5% bupivacaine + 5 ml 1% lidocaine applied in the vicinity of the C3 nerve root.~The MCPB performed using ultrasound-guidance aiming specifically for the interfascia space. Eighteen ml of 0.375% bupivacaine was injected into the interfascia space at the level of C3 vertebral body using a 22G needle (07 x 40 mm).
Study: NCT04362943

Intervention type: DRUG
Intervention: Baricitinib or Anakinra
Description: Treatment with either Baricitinib or Anakinra during hospitalization, in real world, and under usual clinical care.
Study: NCT02501408

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: propriofoot prosthesis
Description: Adaptation of the device and evaluation after 1 month at home using the studied device
Study: NCT04362943

Intervention type: DRUG
Intervention: Baricitinib or Anakinra
Description: Treatment with either Baricitinib or Anakinra during hospitalization, in real world, and under usual clinical care.

Intervention type: DRUG
Intervention: Baricitinib or Anakinra
Description: Treatment with either Baricitinib or Anakinra during hospitalization, in real world, and under usual clinical care.
Study: NCT01202903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: The minimum dose of 0.016 mg/kg/IgE (IU/mL) omalizumab was administered every 4 weeks by subcutaneous injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The minimum dose of 0.016 mg/kg/IgE (IU/mL) placebo was administered every 4 weeks by subcutaneous injection.
Study: NCT01108926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atripla®
Description: All subjects will be administered Atripla® (tenofovir 245 mg plus emtricitabine 200 mg plus efavirenz 600 mg), one tablet orally once daily for 14 days
Study: NCT02614989

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI guided focused ultrasound thalamotomy
Description: MRI guided focused ultrasound thalamotomy
Study: NCT04085601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APL-2
Description: Complement (C3) Inhibitor
Study: NCT01127100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: transdermal fentanyl matrix, gabapentin
Description: transdermal fentanyl matrix: during 1st to 6th days, 12ug/h of fentanyl matrix will be applied. During 7th to 28th days, the dosage of fentanyl matrix will be increased until the pain score decrease not more than 2 every 6 days. The maximal dosage is 100ug/h. During 29th to 56th days, the dosage will be maintained.~Gabapentin: the 1st day, 300mg hs, the 2nd day, 300mg bid, the 3th to 4th days, 300mg tid, the 5th to 6th days, 300mg-300mg-600mg the 7th to 28 days, the dosage will be increased until the pain score decreased not more than 2 and the maximal dose is 2400mg per day. During 29th to 56th days, the dosage will be maintained.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: transdermal fentanyl matrix, gabapentin
Description: transdermal fentanyl matrix: during 1st to 6th days, 12ug/h of fentanyl matrix will be applied. During 7th to 28th days, the dosage of fentanyl matrix will be increased until the pain score decrease not more than 2 every 6 days. The maximal dosage is 100ug/h. During 29th to 56th days, the dosage will be maintained.~Gabapentin: the 1st day, 300mg hs, the 2nd day, 300mg bid, the 3th to 4th days, 300mg tid, the 5th to 6th days, 300mg-300mg-600mg the 7th to 28 days, the dosage will be increased until the pain score decreased not more than 2 and the maximal dose is 2400mg per day. During 29th to 56th days, the dosage will be maintained.
Study: NCT02794129

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Magnetic Resonance Imaging
Study: NCT04207177

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil 500 mg Tab
Description: Twice daily dosing of MMF only for a week before transplantation in this subgroup. All patients will get maintenance treatment With MMF in combination With tacrolimus and steroids after transplantation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus capsule
Description: Twice daily dosing of tacrolimus only for a week before transplantation in this subgroup. All patients will get maintenance treatment With tacrolimus in combination With MMF and steroids after transplantation.
Study: NCT03282669

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal Morphine
Description: Intrathecal Morphine administered in the operating room.
Study: NCT00010257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Dosed to AUC of 6.0, given IV over 30 minutes day 1 of a 21-day cycle, for up to 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 225 mg/m2 given by intravenous (IV) infusion over 3 hours on day 1 of a 21-day cycle, for up to 6 cycles
Study: NCT02627079

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Daily SMS text messaging

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Daily SMS text messaging
Study: NCT03894995

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Installation of ventilation
Description: The intervention is installation of a ventilating structure, in this case a window in the house roof.
Study: NCT01549145

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nimbus Multifunctional Stimulator
Description: A Multifunctional Stimulator (Nimbus by Newmedic, Hemodia) for clinical use. The stimulator is also dedicated for Electrical Promontory Stimulation (EPS)
Study: NCT01491022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ampyra first, then Placebo
Description: 10 mg po bid for 4 weeks followed by placebo 4 weeks.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: placebo first, then Ampyra
Description: placebo
Study: NCT02425137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1/Gemcitabine
Description: Eligible patients will receive gemcitabine 800 mg/m2/day on day 1 and S-1 orally 80-120 mg/day (depending on patient's body surface area (BSA)) on day 1 to 10 in a 2-week cycle.
Study: NCT00313729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Chemotherapy
Study: NCT03790410

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Complex pulmonary rehabilitation
Description: Complex pulmonary rehabilitation program containing breathing exercises, bicycle ergometer conditionings, relaxations, strength and endurance trainings.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Complex pulmonary rehabilitation
Description: Complex pulmonary rehabilitation program containing breathing exercises, bicycle ergometer conditionings, relaxations, strength and endurance trainings.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inspiratory muscle training
Description: The training program contains strengthening exercises on the diaphragm muscle.
Study: NCT01179607

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: M0002

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03320707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Single SC dose of daratumumab will be administered in each of 8 dose cohorts.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo liquid will be administered as SC dose in each of first 7 dose cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rHuPH20
Description: Participants in Cohort 8 will receive single SC dose of rHuPH20 as a part of daratumumab formulation.
Study: NCT00843141

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive computerized training
Description: cognitive computerized training utilizing executive attention tasks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: simple cognitive computerized training
Description: simple computerized cognitive program utilising simple reaction time tasks that do not challenge executive attention